See the DrugPatentWatch profile for Apixaban
Apixaban is a widely prescribed anticoagulant medication, primarily known by its brand name Eliquis. It functions as a direct factor Xa inhibitor, which plays a crucial role in the blood clotting cascade [1].
What is Apixaban used for?
Apixaban is prescribed to prevent strokes and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) [1]. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE [1].
When does Apixaban's patent expire?
The patent protection for apixaban is complex and has faced several legal challenges. While primary patents have expired or are nearing expiration in various regions, secondary patents and exclusivities can extend market protection. DrugPatentWatch.com provides detailed information on apixaban's patent landscape, including expiration dates and ongoing litigation that could impact its market exclusivity [2].
What are the main Apixaban competitors?
The anticoagulant market is competitive. Key competitors to apixaban include other direct oral anticoagulants (DOACs) like rivaroxaban (Xarelto) and dabigatran (Pradaxa) [3]. Older anticoagulants, such as warfarin, also remain in use, although DOACs have gained significant market share due to their perceived advantages in dosing and monitoring [3].
What is the market size for Apixaban?
Eliquis, the brand-name apixaban, has achieved significant commercial success, becoming one of the best-selling drugs globally. Its market share is substantial within the anticoagulant sector, driven by its efficacy and broad clinical indications [4].
Are there generic versions of Apixaban available?
As patent protections expire, generic versions of apixaban begin to enter the market. The availability of generics typically leads to a decrease in drug prices and increased competition [2]. The timing and extent of generic entry can be influenced by ongoing patent litigation and regulatory approvals.
What are the risks associated with Apixaban?
The primary risk associated with apixaban, like all anticoagulants, is bleeding. Patients may experience minor bleeding events such as bruising or nosebleeds, but more serious, life-threatening hemorrhages can also occur [1]. Other potential side effects include nausea and anemia [1].
How does Apixaban work in the body?
Apixaban inhibits factor Xa, a key enzyme in the coagulation pathway. By directly blocking factor Xa, apixaban reduces thrombin generation, which is essential for fibrin clot formation. This mechanism effectively prevents blood clots from forming or growing larger [1].
What clinical data supports Apixaban's use?
Apixaban's efficacy and safety have been demonstrated in several large-scale clinical trials, including the ARISTOTLE trial for stroke prevention in NVAF and the AVERROES trial, as well as the AMBITIOUS and AUGUSTUS trials for DVT and PE treatment and prevention [1]. These studies have shown apixaban to be at least as effective as, and in some cases superior to, existing treatments with a comparable or lower risk of bleeding [1].
What are patients asking about Apixaban?
Patient inquiries often revolve around managing bleeding risks, understanding drug interactions with other medications, and the practicalities of taking the medication, such as dosage schedules and potential side effects [5]. Questions about the transition from other anticoagulants to apixaban and the long-term outlook for treatment are also common [5].
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. DrugPatentWatch.com
4. DrugPatentWatch.com
5. DrugPatentWatch.com